U.S. markets close in 4 hours 56 minutes

Simulations Plus, Inc. (SLP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
62.10-0.41 (-0.66%)
As of 11:02AM EDT. Market open.

Simulations Plus, Inc.

42505 Tenth Street West
Lancaster, CA 93534-7059
United States
661 723 7723
http://www.simulations-plus.com

Sector(s)Healthcare
IndustryHealth Information Services
Full Time Employees129

Key Executives

NameTitlePayExercisedYear Born
Mr. Walter S. WoltoszCo-Founder & Chairman57.5kN/A1945
Mr. Shawn M. O'ConnorChief Exec. Officer506kN/A1960
Mr. John Anthony DiBellaPres of the Lancaster Division293.04kN/A1980
Mr. William FredrickCFO & Sec.N/AN/A1964
Dr. Alexander BergVP of OperationsN/AN/AN/A
Ms. Viera Lukacova Ph.D.Chief ScientistN/AN/AN/A
Ms. Arlene PadronMarketing DirectorN/AN/AN/A
Nguyen NguyenVP of HRN/AN/AN/A
Dr. Michael B. Bolger Ph.D.Founding ScientistN/AN/AN/A
Dr. Thaddeus Henry Grasela Jr., Pharm.D., PharmD, Ph.D.Exec. VP of CognigenN/AN/A1954
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was founded in 1996 and is headquartered in Lancaster, California.

Corporate Governance

Simulations Plus, Inc.’s ISS Governance QualityScore as of April 1, 2021 is 6. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.